Somatic cell nuclear transfer technology ban in Lott cloning bill is objectionable to PhRMA.
Executive Summary
SOMATIC CELL NUCLEAR TRANSFER TECHNOLOGY BAN OBJECTIONABLE TO PhRMA, Pharmaceutical Research & Manufacturers of America Exec VP Judith Bello indicated during a Capitol Hill press conference Feb. 6. Bello cited the specific ban on that technology as a problem with Senate legislation addressing human cloning. "Any ban on any particular technology" would set a "terrible adverse precedent," Bello said.